About Neovacs
Neovacs is a publicly listed company based in Paris (France) founded in 1993. Vaccine manufacturing services are provided by Neovacs CDMO. Neovacs has raised $17.91 million across 10 funding rounds from investors including Debiopharm, Kepler Cheuvreux and Maxim Group. Its chief executive, as recorded, is Hugo Brugiere. Neovacs offers products and services including Kinoide. Its focus areas include Biopharma Outsourcing, CDMO, Biologics and Vaccines.
Company details
Neovacs was established in 1993 in Paris, France, as a contract development and manufacturing organization in the biotechnology sector. Vaccine production processes are handled, including formulation and scaling for clinical and commercial needs. Operations are centered in Europe, with expertise applied to various vaccine types. Leadership is provided by CEO Hugo Brugiere, overseeing facilities compliant with regulatory standards.
- Headquarters Paris, France
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website neovacs.com/fr
- Social LinkedIn
- Legal Name Neovacs Sa
- Annual Revenue$190.09 K (USD)-44.46as on Dec 31, 2025
- Net Profit-$5.76 M (USD)85.12as on Dec 31, 2025
- EBITDA-$6.16 M (USD)20.25as on Dec 31, 2025
- Total Equity Funding$17.91M (USD)
in 10 rounds
- Latest Funding Round$2.56M (USD), Post-IPO
Dec 2018
- InvestorsDebiopharm
& 5 more
Products & Services of Neovacs
Neovacs offers a comprehensive portfolio of products and services, including Kinoide.
Technology for immunotherapy targeting lupus and allergies.
Funding Insights of Neovacs
Neovacs has successfully raised a total of $17.91M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2.56 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17.91M
- Total Rounds 10
- Last Round Post-IPO — $2.56M
- First Round $17.91M
(Jul 2007)
- Investors Count 6
All 10 funding rounds of Neovacs with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2018 | $2.56M | Post-IPO | – | – | |
| Jun 2017 | $4.14M | Post-IPO | – | – | – |
| Jun 2016 | $9.1M | Post-IPO | – | – | – |
| Jul 2015 | $8.33M | Post-IPO | – | – | |
| Nov 2014 | $8.78M | Post-IPO | – | – | |
| May 2013 | $538,702 | Post-IPO | – | – | – |
| Mar 2013 | $9.37M | Post-IPO | – | – | – |
| Apr 2011 | $3.19M | Post-IPO | – | – | |
| Aug 2010 | $1.23M | Post-IPO | – | – | – |
| Jul 2007 | $17.91M | Series B | – | Truffle Capital, Novartis Venture Fund | – |
6 investors in total: 6 institutional.
Investors in Neovacs
Neovacs has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Debiopharm, Kepler Cheuvreux and Maxim Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Truffle Capital is recognized as a leading European venture capital firm. | 2001 | truffle.com | Paris, France | |
| apicap.fr | ||||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
Biopharmaceutical company focused on oncology, infectious diseases, and orphan drugs | 1979 | debiopharm.com | Lausanne, Switzerland | |
Financial advisory services are provided across multiple sectors. | 2002 | maximgrp.com | New York, United States | |
Provider of independent financial services encompassing research, execution, fixed income, structured solutions, corporate finance, and asset management | 1997 | keplercheuvreux.com | Paris, France |
Investor details for Neovacs
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Neovacs
4 people are tracked at Neovacs (3 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Hugo Brugiere | CEO | Leadership |
Vincent Serra | Chief Scientific and Operating Officer | Leadership |
Olivier Dhellin | Director Pharmaceutical Development | Leadership |
katia lemdani | R&d Manager | Team |
Complete people profiles for Neovacs
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Neovacs
Neovacs is a publicly listed company on the EURONEXT with ticker symbol ALNEV in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Apr 2010
- Listed onEuronext: ALNEV
- Listed entityNeovacs SA
- Exchange sectorHealth technology
- ISINFR0014018EV4
- Share price0.20 EUR (+3.42% on the day) · 2026-10-14
- Market capitalisation232,709.00 EUR
- Volume (last session)20
Financials of Neovacs
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 161,780 EUR | -4.9M EUR | -5.2M EUR |
| 2024 | 291,310 EUR | -32.9M EUR | -6.6M EUR |
| 2023 | 533,410 EUR | -8.7M EUR | -6.7M EUR |
| 2022 | 1,110 EUR | -3.5M EUR | -6.3M EUR |
| 2021 | 22,540 EUR | -11.8M EUR | -7.7M EUR |
Detailed financial statements for Neovacs
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Neovacs
4 dated milestones of Neovacs across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Neovacs is founded.
- Funding First funding round of $17.9M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $2.6M.
Web traffic of Neovacs
The website of Neovacs (neovacs.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▼ 23.9% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neovacs
Complete news archive for Neovacs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neovacs
Neovacs was founded in 1993 and raised its 1st funding round 14 years after it was founded.
Neovacs is headquartered in Paris, France.
Hugo Brugiere is the CEO of Neovacs, as recorded in our data.
Neovacs is a funded company, having raised a total of $17.91M across 10 funding rounds to date. The company's 1st funding round was a Series B of $17.91M, raised on Jul 2007.
Annual revenue of Neovacs is $190.09K as on Dec 31, 2025.
Neovacs was established in 1993 in Paris, France, as a contract development and manufacturing organization in the biotechnology sector. Vaccine production processes are handled, including formulation and scaling for clinical and commercial needs. Operations are centered in Europe, with expertise applied to various vaccine types. Leadership is provided by CEO Hugo Brugiere, overseeing facilities compliant with regulatory standards.
Neovacs offers Kinoide.
Yes, Neovacs is publicly traded on EURONEXT under the ticker symbol ALNEV.
Neovacs has 6 investors. Key investors include Debiopharm, Kepler Cheuvreux, Maxim Group, Truffle Capital, and APICAP.